Stifel Maintains Buy on Summit Therapeutics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and raises the price target from $8 to $14.
June 03, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino maintains a Buy rating on Summit Therapeutics and raises the price target from $8 to $14.
The raised price target from $8 to $14 by a reputable analyst at Stifel is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100